CCL5 and pancreatic neoplasm: Circulating levels of C-C motif chemokine ligand 5 (CCL5) have been associated with an unfavorable prognosis in pancreatic cancer treated with capecitabine, the result being associated with a possible CCL5-induced immunosuppressive tumor microenvironment [40,41].